AbivaxABVX
Market Cap: $777M
About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
Employees: 61
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
12% more capital invested
Capital invested by funds: $343M [Q1] → $385M (+$42M) [Q2]
8.12% more ownership
Funds ownership: 38.09% [Q1] → 46.22% (+8.12%) [Q2]
6% more funds holding
Funds holding: 36 [Q1] → 38 (+2) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Laidlaw & Co. Yale Jen 25% 1-year accuracy 1 / 4 met price target | 289%upside $48 | Buy Initiated | 29 Jul 2024 |